Skip to main content

Roivant Sciences Ltd.

ROIV
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001635088

In the last 90 days, Roivant Sciences Ltd. insiders filed 0 open-market purchases and 12 sales; 500 institutions reported holding it in 13F filings for Q2 2026, worth $20.0B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Roivant Sciences Ltd. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
12 filings
6 insiders, $143.4M in total
Insiders trading
6
Net value
−$143.4M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Roivant Sciences Ltd., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Roivant Sciences Ltd.
NameTitleLast reported holdingLast filingFilings, past year
Humes JenniferChief Accounting Officer106,419Sep 22, 20265
Pulik RichardCFO269,681Sep 22, 202611
Manchester Keith SDirector1,753,457Sep 18, 20265
Gold Daniel AllenDirector8,965,815Sep 18, 20266
Oren IlanDirector123,680Sep 18, 20266
Momtazee James CDirector111,959Sep 18, 20266
Fitzgerald MeghanDirector41,162Sep 18, 20266
Epperly Melissa B,Director14,954Sep 18, 20269
Venker EricPresident & Immunovant CEO1,599,154Sep 1, 202617
Sukhatme MayukhPresident & CIO18,630,739Aug 21, 20268
Gline MatthewCEO16,659,945Jul 2, 20264
Torti FrankPresident and Vant Chair13,536,202Jul 2, 20264
QVT Financial LPOther: Director by Deputization13,689,166IndirectJun 30, 20264
Ramaswamy Vivek10% Owner33,653,755Dec 15, 20252
Kumar RakhiChief Accounting Officer162,306Feb 24, 20250
SoftBank Vision Fund L.P.10% Owner73,031,667IndirectOct 2, 20230
SVF Holdings (UK) LLP10% Owner73,031,667IndirectOct 2, 20230
SVF Investments (UK) Ltd10% Owner73,031,667IndirectOct 2, 20230
SB Investment Advisers (UK) Ltd10% Owner73,031,667IndirectOct 2, 20230
Viking Global Investors LP10% Owner12,884,307IndirectJun 26, 20230
Halvorsen Ole Andreas10% Owner12,884,307IndirectJun 26, 20230
Ott David C.10% Owner12,884,307IndirectJun 26, 20230
Viking Global Opportunities Portfolio GP LLC10% Owner12,884,307IndirectJun 26, 20230
Viking Global Opportunities GP LLC10% Owner12,884,307IndirectJun 26, 20230
Viking Global Opportunities Illiquid Investments Sub-Master LP10% Owner12,884,307IndirectJun 26, 20230
Shabet Rose Sharon10% Owner12,884,307IndirectJun 26, 20230
Viking Global Opportunities Parent GP LLC10% Owner12,884,307IndirectJun 26, 20230
Viking Global Performance LLC10% Owner12,884,307IndirectJun 26, 20230
Viking Global Equities II LP10% Owner12,884,307IndirectJun 26, 20230
Viking Long Fund Master Ltd.10% Owner12,884,307IndirectJun 26, 20230
Viking Long Fund GP LLC10% Owner12,884,307IndirectJun 26, 20230
Viking Global Equities Master Ltd.10% Owner12,884,307IndirectJun 26, 20230
Sumitomo Pharma Co., Ltd.10% Owner71,251,083IndirectJun 26, 20230
Sumitomo Chemical Co., Ltd.10% Owner71,251,083IndirectJun 26, 20230
Dexxon Holdings Ltd.10% Owner102,849,443Nov 14, 20220
Oren Dan10% Owner102,849,443Nov 14, 20220
Dexcel Pharma Technologies Ltd.10% Owner102,849,443Nov 14, 20220
Lo AndrewDirector52,142Sep 19, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 17, 2026 (view filing)6:43 PM ETSep 152 daysEpperly Melissa B,DirectorSSale−4.94K$39.74−$196.2K−33.3%9.90K after2 lots10b5-1
Sep 17, 2026 (view filing)6:42 PM ETSep 152 daysFitzgerald MeghanDirectorSSale−5.11K$39.74−$203.2K−12.4%36.1K after2 lots10b5-1
Sep 10, 2026 (view filing)9:00 PM ETSep 82 daysFitzgerald MeghanDirectorSSale−20.0K$39.90−$798.0K−31.8%43.0K after10b5-1
Sep 1, 2026 (view filing)9:00 PM ETAug 284 daysVenker EricPresident & Immunovant CEOSSale−200.0K$35.77−$7.15M−11.1%1.60M after2 lots10b5-1
Aug 21, 2026 (view filing)9:00 PM ETAug 19-212 daysSukhatme MayukhPresident & CIOSSale−335.2K$36.88−$12.4M−1.8%18.6M after3 lots
Aug 18, 2026 (view filing)9:00 PM ETAug 14-184 daysSukhatme MayukhPresident & CIOSSale−664.8K$36.34−$24.2M−3.4%18.6M after4 lots
Jul 29, 2026 (view filing)9:00 PM ETJul 272 daysVenker EricPresident & Immunovant CEOSSale−200.0K$34.95−$6.99M−11.0%1.61M after10b5-1
Jul 2, 2026 (view filing)7:03 PM ETJun 302 daysFitzgerald MeghanDirectorSSale−10.0K$34.90−$349.0K−18.9%43.0K after10b5-1
Jul 1, 2026 (view filing)6:34 PM ETJun 292 daysEpperly Melissa B,DirectorSSale−17.8K$34.38−$610.3K−51.9%16.5K after2 lots10b5-1
Jun 30, 2026 (view filing)Jun 26-304 daysManchester Keith SDirectorSSale−1.44M$34.32−$49.4M−9.5%13.7M after5 lotsDuplicate filing
Jun 30, 2026 (view filing)Jun 30Same dayManchester Keith SDirectorSSale−200.0K$35.45−$7.09M−10.3%1.75M after
Jun 30, 2026 (view filing)Jun 26-304 daysGold Daniel AllenDirectorSSale−1.44M$34.32−$49.4M−9.5%13.7M after5 lotsDuplicate filing
Jun 30, 2026 (view filing)Jun 26-304 daysQVT Financial LPOther: Director by DeputizationSSale−1.44M$34.32−$49.4M−9.5%13.7M after5 lots
Jun 29, 2026 (view filing)Jun 25-264 daysSukhatme MayukhPresident & CIOSSale−1.00M$34.11−$34.1M−5.1%18.7M after2 lots
Jun 26, 2026 (view filing)Jun 242 daysVenker EricPresident & Immunovant CEOSSale−200.0K$33.16−$6.63M−11.0%1.61M after2 lots10b5-1
May 22, 2026 (view filing)May 22Same dayVenker EricPresident & Immunovant CEOSSale−200.0K$30.27−$6.05M−11.0%1.61M after10b5-1
Apr 22, 2026 (view filing)Apr 202 daysVenker EricPresident & Immunovant CEOSSale−200.0K$29.59−$5.92M−10.8%1.65M after10b5-1
Apr 20, 2026 (view filing)Apr 164 daysGline MatthewCEOSSale−289.8K$29.16−$8.45M−1.7%16.7M after
Apr 10, 2026 (view filing)Apr 82 daysHumes JenniferChief Accounting OfficerSSale−13.5K$28.37−$384.1K−13.9%84.2K after
Mar 30, 2026 (view filing)Mar 264 daysFitzgerald MeghanDirectorSSale−70.0K$27.45−$1.92M−62.0%43.0K after
Mar 19, 2026 (view filing)Mar 172 daysVenker EricPresident & Immunovant CEOSSale−200.0K$28.24−$5.65M−10.8%1.65M after10b5-1
Mar 18, 2026 (view filing)Mar 162 daysEpperly Melissa B,DirectorSSale−41.9K$28.68−$1.20M−72.6%15.8K after
Feb 23, 2026 (view filing)Feb 19-234 daysTorti FrankPresident and Vant ChairSSale−3.00M$27.35−$82.0M−17.9%13.7M after3 lots10b5-1
Feb 18, 2026 (view filing)Feb 135 daysVenker EricPresident & Immunovant CEOSSale−200.0K$26.49−$5.30M−10.8%1.65M after10b5-1
Feb 13, 2026 (view filing)Feb 11-132 daysManchester Keith SDirectorSSale−1.23M$26.64−$32.7M−7.5%15.1M after5 lotsDuplicate filing
Feb 13, 2026 (view filing)Feb 11-132 daysGold Daniel AllenDirectorSSale−1.23M$26.64−$32.7M−7.5%15.1M after5 lotsDuplicate filing
Feb 13, 2026 (view filing)Feb 11-132 daysQVT Financial LPOther: Director by DeputizationSSale−1.23M$26.64−$32.7M−7.5%15.1M after5 lots
Feb 11, 2026 (view filing)Feb 92 daysSukhatme MayukhPresident & CIOSSale−339.4K$26.47−$8.99M−1.7%19.1M after
Jan 14, 2026 (view filing)Jan 122 daysVenker EricPresident & Immunovant CEOSSale−200.0K$21.92−$4.38M−10.8%1.65M after10b5-1
Dec 31, 2025 (view filing)Dec 29-312 daysSukhatme MayukhPresident & CIOSSale−1.33M$21.72−$28.9M−6.2%20.3M after2 lots
Dec 29, 2025 (view filing)Dec 236 daysPulik RichardCFOSSale−406.7K$22.43−$9.12M−62.9%239.4K after2 lots
Dec 29, 2025 (view filing)Dec 23-246 daysVenker EricPresident & Immunovant CEOSSale−275.0K$22.47−$6.18M−14.3%1.65M after2 lots
Dec 19, 2025 (view filing)Dec 172 daysSukhatme MayukhPresident & CIOSSale−26.8K$23.09−$619.5K−0.1%18.9M after
Dec 18, 2025 (view filing)Dec 16-172 daysGold Daniel AllenDirectorSSale−1.69M$23.05−$39.1M−9.4%16.4M after5 lotsDuplicate filing
Dec 18, 2025 (view filing)Dec 16-172 daysManchester Keith SDirectorSSale−1.69M$23.05−$39.1M−9.4%16.4M after5 lotsDuplicate filing
Dec 18, 2025 (view filing)Dec 16-172 daysQVT Financial LPOther: Director by DeputizationSSale−1.69M$23.05−$39.1M−9.4%16.4M after5 lots
Dec 17, 2025 (view filing)Dec 152 daysGline MatthewCEOSSale−1.74M$21.68−$37.7M−8.5%18.6M after3 lots
Dec 15, 2025 (view filing)Dec 11-154 daysRamaswamy Vivek10% OwnerSSale−3.10M$21.89−$67.9M−8.3%34.1M after3 lots
Dec 11, 2025 (view filing)Dec 92 daysVenker EricPresident & Immunovant CEOSSale−200.0K$20.85−$4.17M−11.8%1.50M after10b5-1
Nov 21, 2025 (view filing)Nov 192 daysManchester Keith SDirectorSSale−1.30M$20.23−$26.3M−6.7%18.0M after4 lotsDuplicate filing
Nov 21, 2025 (view filing)Nov 192 daysGold Daniel AllenDirectorSSale−1.30M$20.23−$26.3M−6.7%18.0M after4 lotsDuplicate filing
Nov 21, 2025 (view filing)Nov 192 daysQVT Financial LPOther: Director by DeputizationSSale−1.30M$20.23−$26.3M−6.7%18.0M after4 lots
Nov 17, 2025 (view filing)Nov 13-174 daysRamaswamy Vivek10% OwnerSSale−1.85M$20.46−$37.9M−5.2%33.7M after3 lots
Nov 7, 2025 (view filing)Nov 7Same dayVenker EricPresident & Immunovant CEOSSale−200.0K$20.22−$4.04M−11.7%1.50M after10b5-1
Oct 17, 2025 (view filing)Oct 15-172 daysVenker EricPresident & Immunovant CEOSSale−851.4K$16.99−$14.5M−36.1%1.50M after3 lots10b5-1
Oct 14, 2025 (view filing)Oct 9-135 daysVenker EricPresident & Immunovant CEOSSale−125.7K$16.29−$2.05M−7.7%1.50M after2 lots10b5-1
Oct 8, 2025 (view filing)Oct 6-82 daysVenker EricPresident & Immunovant CEOSSale−665.2K$16.21−$10.8M−30.7%1.50M after3 lots10b5-1
Sep 23, 2025 (view filing)Sep 19-234 daysVenker EricPresident & Immunovant CEOSSale−1.71M$14.92−$25.5M−53.2%1.50M after4 lots10b5-1
Sep 18, 2025 (view filing)Sep 18Same dayGline MatthewCEOPPurchase+3.31K$15.07+$50.0K0.0%17.3M after
Sep 5, 2025 (view filing)Sep 3-52 daysRamaswamy Vivek10% OwnerSSale−1.78M$12.65−$22.5M−4.8%35.5M after3 lots